

Giulia Maria Sancesario

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1612249/publications.pdf>

Version: 2024-02-01

40
papers

1,620
citations

279798

23
h-index

302126

39
g-index

40
all docs

40
docs citations

40
times ranked

2783
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau and Amyloid- β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters. <i>Frontiers in Neurology</i> , 2022, 13, 748599.	2.4	8
2	How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 87-92.	2.2	1
3	Artificial Intelligence for Alzheimer's Disease: Promise or Challenge?. <i>Diagnostics</i> , 2021, 11, 1473.	2.6	38
4	Biobanking for Neurodegenerative Diseases: Challenge for Translational Research and Data Privacy. <i>Neuroscientist</i> , 2021, , 107385842110366.	3.5	2
5	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. <i>Neurobiology of Aging</i> , 2020, 90, 119-124.	3.1	41
6	Amyloid- β 242/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1171-1178.	2.6	11
7	AD biomarker discovery in CSF and in alternative matrices. <i>Clinical Biochemistry</i> , 2019, 72, 52-57.	1.9	15
8	Association between physical activity and dementia's risk factors in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 319-325.	2.8	26
9	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. <i>Journal of Neural Transmission</i> , 2018, 125, 673-679.	2.8	31
10	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 38.	3.4	25
11	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 525-532.	2.6	59
12	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	2.8	25
13	Assessment of serum uric acid as risk factor for tauopathies. <i>Journal of Neural Transmission</i> , 2017, 124, 1105-1108.	2.8	16
14	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1621-1625.	2.8	27
15	Effects of parasitic infection and reproduction on corticosterone plasma levels in Galápagos land iguanas, <i>Conolophus marthae</i> and <i>C. subcristatus</i> . <i>Ecology and Evolution</i> , 2017, 7, 6046-6055.	1.9	9
16	Amyloid- β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 390.	2.9	21
17	The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1659-1666.	2.6	17
18	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2040-2049.	6.4	73

#	ARTICLE	IF	CITATIONS
19	Plasma concentrations of progesterone and estradiol and the relation to reproduction in Galápagos land iguanas, <i>Conolophus marthae</i> and <i>C. subcristatus</i> (Squamata, Iguanidae). <i>Animal Reproduction Science</i> , 2016, 172, 105-113.	1.5	7
20	Cerebrospinal Fluid A β Levels: When Physiological Become Pathological State. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 921-925.	3.9	41
21	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. <i>Frontiers in Neurology</i> , 2015, 6, 86.	2.4	39
22	CSF lactate levels, β , proteins, cognitive decline: a dynamic relationship in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 655-659.	1.9	108
23	How many biomarkers to discriminate neurodegenerative dementia?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 314-326.	6.1	16
24	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1498.	9.0	262
25	Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. <i>Multiple Sclerosis Journal</i> , 2014, 20, 304-312.	3.0	117
26	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. <i>Journal of Neurology</i> , 2014, 261, 1832-1836.	3.6	25
27	CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiprone—a case report. <i>Neurological Sciences</i> , 2014, 35, 1151-1152.	1.9	7
28	Cerebrospinal Fluid Levels of a 20 kDa NH2 Fragment of Human Tau Provide a Novel Neuronal Injury Biomarker in Alzheimer's Disease and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 211-226.	2.6	40
29	Transient global amnesia: Linked to a systemic disorder of amino acid catabolism?. <i>Journal of Neurology</i> , 2013, 260, 1429-1432.	3.6	4
30	Frailty Among Alzheimer's Disease Patients. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 507-511.	1.4	36
31	The Load of Amyloid- β Oligomers is Decreased in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 865-878.	2.6	31
32	Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease. <i>Molecular Therapy</i> , 2012, 20, 870-876.	8.2	125
33	Plasmin system of Alzheimer's disease patients: CSF analysis. <i>Journal of Neural Transmission</i> , 2012, 119, 763-769.	2.8	18
34	Cerebrospinal fluid levels of A β 242 relationship with cholinergic cortical activity in Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2012, 119, 771-778.	2.8	31
35	Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1301-1312.	3.0	54
36	Glaucoma progression associated with altered cerebral spinal fluid levels of amyloid beta and tau proteins. <i>Clinical and Experimental Ophthalmology</i> , 2011, 39, 279-281.	2.6	40

#	ARTICLE	IF	CITATIONS
37	Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1299-1312.	2.3	25
38	Salivary miRNAome profiling uncovers epithelial and proliferative miRNAs with differential expression across dentition stages. <i>Cell Cycle</i> , 2011, 10, 3359-3368.	2.6	10
39	Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid- β CSF Levels in Multiple Sclerosis. <i>Neuropsychopharmacology</i> , 2011, 36, 559-568.	5.4	95
40	A β 1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible A β 1-42 aggregation?. <i>Experimental Neurology</i> , 2010, 223, 371-376.	4.1	44